|Other Names||Calcipressin-3, Down syndrome candidate region 1-like protein 2, Myocyte-enriched calcineurin-interacting protein 3, MCIP3, Regulator of calcineurin 3, RCAN3, DSCR1L2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6310a was selected from the N-term region of human DSCR1L2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development (By similarity).|
|Tissue Location||Highest expression in heart, skeletal muscle kidney, liver and peripheral blood leukocytes. Lower expression in all other tissues|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DSCR1L2 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A, and may play a role during central nervous system development. Highest expression occurs in heart, skeletal muscle kidney, liver and peripheral blood leukocytes.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.